Edwards Lifesciences Longtime Chair To Retire
By Ben Glickman
Edwards Lifesciences said Tuesday that chair Michael Mussallem planned to retire about a year after stepping down as chief executive.
The Irvine, Calif.-based company said in a regulatory filing that Mussallem, who served as CEO of Edwards from 2000 to 2023, is expected to be succeeded as chair by Nicholas Valeriani, an independent director.
Mussallem retired as CEO at the 2023 annual meeting, transitioning into the non-executive chair role. He was succeeded in the CEO role by Bernard Zovighian.
The company's annual meeting is scheduled for May 7.
Edwards said in the filing that board member Martha Marsh had reached the retirement age outlined in the company's governance guidelines.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 26, 2024 16:42 ET (20:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations